Question 1

What is the goal of plasmapheresis in patients who will be receiving an ABO-incompatible kidney transplant?

Accepted Answer

A) Decrease white blood cell count 
B) Decrease hemagglutinin titers 
C) Increase haptoglobin 
D) Increase hemoglobin 
A) Decrease white blood cell count 
B) Decrease hemagglutinin titers 
C) Increase haptoglobin 
D) Increase hemoglobin B

Question 2

Transfusion-associated graft versus host disease (TA-GVHD)is

Accepted Answer

A) prevented through leukoreduction 
B) almost universally fatal 
C) caused by engraftment of donor B lymphoctyes 
D) most often diagnosed in immunocompetent patients 
A) prevented through leukoreduction 
B) almost universally fatal 
C) caused by engraftment of donor B lymphoctyes 
D) most often diagnosed in immunocompetent patients B

Question 3

Which of the following is a self-limited process that subsides with donor lymphocyte death?

Accepted Answer

A) Graft versus host disease 
B) Hyperacute rejection 
C) Iron overload 
D) Passenger lymphocyte syndrome 
A) Graft versus host disease 
B) Hyperacute rejection 
C) Iron overload 
D) Passenger lymphocyte syndrome D

Question 4

What is the recommended hematocrit in patients with end-stage renal disease?

Accepted Answer

A) 22-25% (0.22-0.25) 
B) 28-33% (0.28-0.33) 
C) 33-36% (0.33-0.36) 
D) 36-42% (0.36-0.42) 
A) 22-25% (0.22-0.25) 
B) 28-33% (0.28-0.33) 
C) 33-36% (0.33-0.36) 
D) 36-42% (0.36-0.42)

Question 5

Which of the following best describes an exchange transfusion?

Accepted Answer

A) Removal of patient's plasma and replacement with normal saline 
B) Removal of patient's red blood cells and replacement with donor red blood cells 
C) Transfusion of phenotype-matched donor red blood cells 
D) Transfusion of irradiated donor red blood cells 
A) Removal of patient's plasma and replacement with normal saline 
B) Removal of patient's red blood cells and replacement with donor red blood cells 
C) Transfusion of phenotype-matched donor red blood cells 
D) Transfusion of irradiated donor red blood cells

Question 6

Which of the following is an oral iron chelator?

Accepted Answer

A) Deferasirox 
B) Deferoxamine 
C) Dexamethasone 
D) Dimercaprol 
A) Deferasirox 
B) Deferoxamine 
C) Dexamethasone 
D) Dimercaprol

Question 7

Approximately how many patients with hemophilia B form an inhibitor?

Accepted Answer

A) 35% 
A) 35%

Question 8

Donor and patient red blood cells are typically matched for which antigens when a patient with sickle cell disease is going to be transfused?

Accepted Answer

A) C,c,E,e 
B) C,E,K 
C) E,K,S 
D) M,N,S 
A) C,c,E,e 
B) C,E,K 
C) E,K,S 
D) M,N,S

Question 9

Hemophilia A is managed by which of the following therapies?

Accepted Answer

A) Exchange transfusion 
B) Factor replacement 
C) Immune suppression 
D) Therapeutic plasmapheresis 
A) Exchange transfusion 
B) Factor replacement 
C) Immune suppression 
D) Therapeutic plasmapheresis

Question 10

Which is the most common inherited disease in people of African ethnicity?

Accepted Answer

A) Hemophilia A 
B) Hemophilia B 
C) Sickle cell disease 
D) von WilLeᵇrand's disease 
A) Hemophilia A 
B) Hemophilia B 
C) Sickle cell disease 
D) von WilLeᵇrand's disease

Question 11

A kidney from a donor typed as which ABO group is less likely to be rejected if transplanted into a group O patient?

Accepted Answer

A) A₁ 
B) A₂ 
C) AB 
D) B 
A) A₁ 
B) A₂ 
C) AB 
D) B

Question 12

Which of the following vitamins is stored in the liver?

Accepted Answer

A) B6 
B) C 
C) E 
D) K 
A) B6 
B) C 
C) E 
D) K

Question 13

The goal of preventative therapy in patients with sickle cell anemia who have had a stroke is to maintain a ____________.

Accepted Answer

A) hemoglobin level above 10 g/dL (100 g/L) 
B) hemoglobin S level below 30% 
C) hemoglobin S level of approximately 40% 
D) hematocrit level of 33-36% (0.33-0.36) 
A) hemoglobin level above 10 g/dL (100 g/L) 
B) hemoglobin S level below 30% 
C) hemoglobin S level of approximately 40% 
D) hematocrit level of 33-36% (0.33-0.36)

Question 14

Red blood cell and platelet transfusions are used as supportive therapy in patients who have undergone a hematopoietic progenitor cell (HPC)transplant until when?

Accepted Answer

A) Chemotherapy is complete 
B) CMV reactivation occurs 
C) Engraftment occurs 
D) Factor levels reach 70% 
A) Chemotherapy is complete 
B) CMV reactivation occurs 
C) Engraftment occurs 
D) Factor levels reach 70%

Question 15

Hemophilia B is due to deficiency in what coagulation factor?

Accepted Answer

A) VII 
B) VIII 
C) IX 
D) X 
A) VII 
B) VIII 
C) IX 
D) X

Question 16

Apheresis therapy to remove white blood cells is used most commonly in what disease?

Accepted Answer

A) Acute leukemia 
B) Chronic leukemia 
C) Lymphoma 
D) Multiple myeloma 
A) Acute leukemia 
B) Chronic leukemia 
C) Lymphoma 
D) Multiple myeloma

Question 17

Hemophilia A is due to deficiency in what coagulation factor?

Accepted Answer

A) VII 
B) VIII 
C) IX 
D) X 
A) VII 
B) VIII 
C) IX 
D) X

Question 18

Which blood product is transfused to raise coagulation factor levels in patients with liver disease who are bleeding?

Accepted Answer

A) Cryoprecipitate 
B) Factor VII 
C) Fresh frozen plasma 
D) Vitamin K 
A) Cryoprecipitate 
B) Factor VII 
C) Fresh frozen plasma 
D) Vitamin K

Question 19

Sickle cells that occlude blood vessels cause all of the following except

Accepted Answer

A) Iron overload 
B) Organ damage 
C) Stroke 
D) Tissue ischemia 
A) Iron overload 
B) Organ damage 
C) Stroke 
D) Tissue ischemia

Question 20

All of the following are common manifestations of cytomegalovirus (CMV)disease except

Accepted Answer

A) Anemia 
B) Gastroenteritis 
C) Hepatitis 
D) Pneumonia 
A) Anemia 
B) Gastroenteritis 
C) Hepatitis 
D) Pneumonia

Exam 17: Transfusion Support of Selected Patient Populations

What is the goal of plasmapheresis in patients who will be receiving an ABO-incompatible kidney transplant?

Transfusion-associated graft versus host disease (TA-GVHD)is

Which of the following is a self-limited process that subsides with donor lymphocyte death?

What is the recommended hematocrit in patients with end-stage renal disease?

Which of the following best describes an exchange transfusion?

Which of the following is an oral iron chelator?

Approximately how many patients with hemophilia B form an inhibitor?

Donor and patient red blood cells are typically matched for which antigens when a patient with sickle cell disease is going to be transfused?

Hemophilia A is managed by which of the following therapies?

Which is the most common inherited disease in people of African ethnicity?

A kidney from a donor typed as which ABO group is less likely to be rejected if transplanted into a group O patient?

Which of the following vitamins is stored in the liver?

The goal of preventative therapy in patients with sickle cell anemia who have had a stroke is to maintain a ____________.

Red blood cell and platelet transfusions are used as supportive therapy in patients who have undergone a hematopoietic progenitor cell (HPC)transplant until when?

Hemophilia B is due to deficiency in what coagulation factor?

Apheresis therapy to remove white blood cells is used most commonly in what disease?

Hemophilia A is due to deficiency in what coagulation factor?

Which blood product is transfused to raise coagulation factor levels in patients with liver disease who are bleeding?

Sickle cells that occlude blood vessels cause all of the following except

All of the following are common manifestations of cytomegalovirus (CMV)disease except

The Immune Process: the Origin and Interaction Between Antigens and Antibodies

Immunogenetics: the Origin of Antigens

Blood Bank Applications of Antigenantibody Reactions

Abo and Hh Blood Group Systems

Rh, Rhag, and Lw Blood Group Systems

Other Blood Group Systems

Pretransfusion and Compatibility Testing

Identification of Unexpected Antibodies

Donor Selection, Phlebotomy, and Required Testing

Blood Products: Preparation, Storage, and Shipment of Blood Components

Component Therapy and Massive Transfusion

Adverse Reactions to Transfusion

Transfusion-Transmitted Infections

Perinatal and Neonatal Transfusion Issues

Autoimmune and Drug-Induced Immune Hemolytic Anemias

Platelet Refractory Patients

Human Histocompatibility

Methods in Parentage Testing

Transfusion Safety and Regulatory Issues

Quality Assurance

Filters